| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
T23247-1mg |
98% | ￥18300.00 |
货期：2-4周 | - | - | - | - |
|
| 体内研究： | Ipenoxazone is a potent and centrally acting muscle relaxant. An intravenous injection of 2 mg/kg Ipenoxazone causes a reduction of electromyographic activity which reaches a maximum within 3 min after the injection. Within 1 min after the injection of Ipenoxazone at a dose of 4 mg/kg, the blood pressure changes from a control level of 138±9 mmHg to a minimum level of 98±9 mmHg (n=6) but it rapidly returns to the control level within 1 to 2 min, while the rigidity is still reduced significantly at that time. High doses (greater than 30 mg/kg i.p.) of Ipenoxazone produces a transient and dose-dependent sedation in almost all mice about 5 min after its administration. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 参考文献： | 1. Kimura A, et al. Inhibitory effects of a new, potent, centrally acting muscle relaxant, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5- phenyl-1,3-oxazolidin-2-one (NC-1200) on micturition contractions of the bladder in rats. Eur J Pharmacol. 1988 Jul 26;152(1-2):55-62. 2. Masaki M, et al. A new class of potent centrally acting muscle relaxants: pharmacology of oxazolidinones in rat decerebrate rigidity. Br J Pharmacol. 1986 Sep;89(1):219-28. |
||||||||||||||||||||
| 保存条件： | RT | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京